Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infant formula and diarrhea

This article was originally published in The Tan Sheet

Executive Summary

Infants with diarrhea fed soy-based formula with sucrose had significantly lower stool output and shorter duration of diarrhea than infants fed soy-based formula with lactose, Ibrahim Fayad, MD, Cairo University, et al., conclude in a study published in the July Archives of Pediatric and Adolescent Medicine. Researchers randomized 200 male infants with diarrhea and dehydration to receive one of the two formulas after treatment with oral rehydration solution, of which 172 finished the protocol. "If soy-based formula is used during a diarrheal episode, a lactose-free formula is preferred," the study concludes. Archives editor Catherine DeAngelis, MD, says it "looks like there's no need for anyone to manufacture a soy-based formula with lactose." Wyeth-Ayerst Nutritionals supported the study; the firm's Nursoy liquid (sucrose) and powder (lactose) formulas were used in the trial

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel